Leukemia Clinical Trials

59 studies are recruiting for leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

   To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   2 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06229912 on ClinicalTrials.gov

2. Mosaic Trial for Stem Cell Transplant Recipients

   The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recru…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Georgetown University School of Medicine, Washington D.C., District of Columbia

   Locations

   3 in total

   Run by

   Northwestern University

   See if you can join NCT06960993 on ClinicalTrials.gov

3. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital Colorado, Aurora, Colorado

   Locations

   6 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

4. Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

   RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic c…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT01137643 on ClinicalTrials.gov

5. HEME Home Transfusion Program

   This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancie…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06487247 on ClinicalTrials.gov

6. Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

   Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically in…

   Stage

   Not phased

   Ages

   5 and older

   Site

   Children s Hospital of Los Angeles, Los Angeles, California

   Locations

   3 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05237986 on ClinicalTrials.gov

7. Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

   This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn …

   Stage

   Not phased

   Ages

   Any age

   Site

   Children's Hospital of Alabama, Birmingham, Alabama

   Locations

   164 in total

   Run by

   Children's Oncology Group

   See if you can join NCT00736749 on ClinicalTrials.gov

8. A Study of Revumenib and Mezigdomide in People With Leukemia

   The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07356154 on ClinicalTrials.gov

9. Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

   The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sylvester Comprehensive Cancer Center, Miami, Florida

   Locations

   3 in total

   Run by

   University of Miami

   See if you can join NCT05745285 on ClinicalTrials.gov

10. Rutgers University Study of the Genetics of Blood Cancers

    The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct genetic analyses to identify novel variants and further study known variant…

    Stage

    Not phased

    Ages

    18 to 110

    Site

    Rutgers University, Piscataway, New Jersey

    Run by

    Rutgers, The State University of New Jersey

    See if you can join NCT07714044 on ClinicalTrials.gov

11. Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

    To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control…

    Stage

    Phase 2

    Ages

    1 to 25

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05645718 on ClinicalTrials.gov

12. Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

    This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not r…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Weill Cornell, New York, New York

    Locations

    64 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT06824168 on ClinicalTrials.gov

13. A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

    This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy. Primary objective: - To estimate the rate of bacterial bloodstream infection in pedi…

    Stage

    Phase 1

    Ages

    Up to 25

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT06810583 on ClinicalTrials.gov

14. Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

    This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06907797 on ClinicalTrials.gov

15. Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

    This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    3 in total

    Run by

    Hannah Choe, MD

    See if you can join NCT07249346 on ClinicalTrials.gov

16. Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

    The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to…

    Stage

    Phase 1

    Ages

    1 to 25

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06408194 on ClinicalTrials.gov

17. CIML NK Cells With Venetoclax for AML

    The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML) with measurab…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06152809 on ClinicalTrials.gov

18. Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

    This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML). The names of the study drugs involved in this research …

    Stage

    Phase 1

    Ages

    18 to 90

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Jacqueline Garcia, MD

    See if you can join NCT07439211 on ClinicalTrials.gov

19. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    45 in total

    Run by

    Kura Oncology, Inc.

    See if you can join NCT06001788 on ClinicalTrials.gov

20. Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

    Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's…

    Stage

    Not phased

    Ages

    19 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT04898790 on ClinicalTrials.gov

21. ALL Backbone in AYAs

    The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of …

    Stage

    Phase 2

    Ages

    18 to 51

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT07227584 on ClinicalTrials.gov

22. DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

    The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatm…

    Stage

    Not phased

    Ages

    60 and older

    Site

    Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06296368 on ClinicalTrials.gov

23. Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)

    Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies. Survival rates have improved over the years, but many children still experience long-term side effects from treatment…

    Stage

    Not phased

    Ages

    6 and older

    Site

    University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07634653 on ClinicalTrials.gov

24. Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

    The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied. Cladribine is designed to interfere with the cel…

    Stage

    Phase 2

    Ages

    60 and older

    Site

    University of Texas MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT01515527 on ClinicalTrials.gov

25. Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

    This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and…

    Stage

    Not phased

    Ages

    Up to 30

    Site

    Connecticut Children's Medical Center, Hartford, Connecticut

    Locations

    8 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04968834 on ClinicalTrials.gov